Clinical Trials Logo

Lymphoid Leukemia clinical trials

View clinical trials related to Lymphoid Leukemia.

Filter by:
  • Recruiting  
  • Page 1

NCT ID: NCT05871008 Recruiting - Breast Cancer Clinical Trials

Integrated Actionable Aging Assessment for Cancer Patients Pilot

Start date: March 1, 2024
Phase: N/A
Study type: Interventional

Aging is the greatest risk factor for cancer incidence and mortality. Geriatric screening is recommended to help with treatment discussions, inform intensity of treatment, and identify supportive care needs. Despite a strong evidence base, geriatric assessments are not implemented routinely in oncologic clinics. Similarly, important information on social determinants of health, mental health, and health behaviors are inconsistently assessed, and almost never in an integrated fashion. In an effort to support clinicians delivering the recommended goal-concordant care, the investigators will integrate assessment of geriatric issues, health behaviors, mental health, and social determinants of health into an efficient, actionable contextual assessment system for older cancer patients called Integrated Aging Assessment for Action for Cancer Patients (IA3-CP). The investigators will use D&I strategies including co-creation engagement approaches and form-function methods to develop workflow processes that feasibly integrate the IA3-CP into usual initial assessment with the oncology team. Our objective is to develop and conduct a randomized pilot of the IA3-CP system and hypothesize that our results will show it can be implemented consistently, acted on, improve quality of care, and enhance patient-provider interactions.

NCT ID: NCT05507827 Recruiting - Lymphoid Leukemia Clinical Trials

Safety of Myeloablative Conditioning, Orca-T, and Allogeneic, Donor-Derived CD19/CD22-CAR (Chimeric Antigen Receptor) T Cells in Adults With B-cell Acute Lymphoblastic Leukemia (ALL)

Start date: August 18, 2022
Phase: Phase 1
Study type: Interventional

To assess the safety of administering allogenic, donor-derived CD19/CD22-CAR T cells that meet established release specifications in adults with B-cell ALL following a myeloablative conditioning regimen and Orca-T to determine if this will augment graft versus leukemia without increasing acute GVHD or graft failure.

NCT ID: NCT00801580 Recruiting - Lymphoid Leukemia Clinical Trials

My-HyperCVAD in the Treatment of Relapsed Refractory Adult Acute Lymphoid Leukemia

Start date: March 2008
Phase: Phase 2
Study type: Interventional

The patient receive 2 different drug combinations on this study. The first combination will consist of an intensive chemotherapy regimen (cyclophosphamide, mesna, methotrexate, doxorubicin liposomal or doxorubicin, vincristine, ARA-C (cytarabine) and dexamethasone). The second combination will consist of another intensive chemotherapy regimen (methotrexate and Ara-C [cytarabine]).